88 results about "Viral matrix protein" patented technology

The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a. The invention further includes a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes the Japanese B encephalitis virus capsid protein, pre-matrix protein, envelope glycoprotein and non-structural proteins NS1 and NS2a. The invention further includes a vaccine and a method to produce that vaccine.

The invention provides viral vector formulations and methods of uses thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. The formulations include a vector and suitable amounts of empty capsids, viral genome-containing capsids, or viral capsid proteins which are optionally chemically or structurally modified and which bind to neutralizing anti-AAV antibodies thereby reducing or preventing antibody-mediated clearance of the vector, but still allowing the genome-containing (therapeutic) vector to transduce target cells and achieve therapeutic gene transfer.

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Described herein are vaccines and the use of naked DNA and / or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and / or the 1957 H2N2 and / or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and / or RNA encoding Neuraminidase (NA) and / or matrix protein (M) and / or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and / or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed.

Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a. The invention further includes a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes the Japanese B encephalitis virus capsid protein, pre-matrix protein, envelope glycoprotein and non-structural proteins NS1 and NS2a. The invention further includes a vaccine and a method to produce that vaccine.

Matrix-enhancing molecules, such as TGF-β, are conjugated to or immobilized on scaffolds to increase ECM production by cells for tissue engineering, tissue regeneration and wound healing applications. The matrix-enhancing molecule is conjugated to a tether, such as polyethylene glycol (PEG) monoacrylate, for attachment to a tissue engineering or cell growth scaffold. The matrix-enhancing molecule retains activity after attachment to the scaffold, and causes cells growing in or on the scaffold to increase extracellular matrix (ECM) production, without substantially increasing proliferation of the cells, even when the scaffold additionally contains cell adhesion ligands. The increased ECM produced by the cells aids in maintaining the integrity of the scaffold, particularly when the scaffold is degradable, either by hydrolysis or by enzymatic degradation.

Disclosed is a recombinant attenuated coxsackievirus B4 virion which is engineered to contain a heterologous nucleic acid within the open reading frame of its genome, wherein the heterologous nucleic acid encodes a heterologous polypeptide which is expressed by the virion. Specific examples of attenuated coxsackievirus B4 virions suitable for use in the present invention are CB4-P and JVB. In one embodiment the heterologous nucleic acid is inserted into the P1 region of the genome such that the heterologous polypeptide is expressed as a fusion of a viral capsid protein. Methods of use of the recombinant attenuated coxsackievirus B4 virion include inducing an immune response in an individual to the heterologous polypeptide contained therein.

The invention relates to a method for preparing for organization project cell epimatrix, which adopts animal stromatin and desmocyte as raw material. It comprises: preparing for the culture liquid, extracting the stromatin, preparing for the cell-stromatin culture material, preparing for the cell epimatrix, dispelling the cell by freezing, and sterilization sanitizing packaging material and so on.

An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.

The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin. With added peptides which boost the collagen and other matrix protein, Triterpenoid peptides provide a complete protection against pre mature ageing and functions as a best anti ageing ingredient.

The present invention relates to the use of enamel matrix, enamel matrix derivatives and / or enamel matrix proteins as therapeutic and / or cosmetic agents. These substances are used for the manufacture of a pharmaceutical and / or cosmetic composition for actively inducing, guiding and / or stimulating connective tissue growth and thus to prevent connective tissue scarring and / or contraction in a wound cavity and / or tissue defect that is characterized by a substantial loss of tissue. The invention comprises, in particular, the use of active enamel substances for guided connective soft tissue growth and resistance to contraction in deep cavity shaped wounds following loss or removal of significant volumes of tissue, such as e.g., after surgical removal of a tumor and especially in combination with radiation therapy.

The invention provides building and application of an M protein three-amino acid site-mutated vesicular stomatitis virus (VSV) carrier for pigs. The VSV carrier is matrix protein (M) three-amino acid site-mutated recombinant virus VSV-MT, the 51st-site methionine of the virus M protein is knocked out, the 221st-site valine of the virus M protein is mutated into phenylalanine, and the 226th-site glycine of the virus M protein is mutated into arginine. The VSV carrier is extremely low in pathogenicity, high in safety, capable of effectively stimulate a body to produce protective immune response, applicable to vaccine or vaccine carrier preparation, and promising in application prospect.

The present invention relates to a combination of agents, including an anti-proliferative agent, an anti-inflammatory agent, an anti-growth factor, and an extracellular matrix (ECM) molecule coated on a stent to prevent acute and subacute thrombosis, enhance endothelial in-growth, and prevent neointimal hyperplasia, and / or suppress neovascularization, and thereby reduce restenosis rates for drug eluting stents. The present invention also relates to methods of using such multiple drug eluting stents for the treatment of heart disease and other vascular conditions.

Virus like particles comprising a fusion protein and substantially free of nucleic acid, wherein the fusion protein comprises a plant viral coat protein and a target protein, are provided. Immunogenic compositions comprising the virus like particles can be administered to subjects to induce protective immune responses in the subjects. Methods of producing the virus like particles are also provided.

The invention discloses a method for preparing low-immunogenicity pig dermal support. The method comprise the following steps of: (1) preparing double fault derma; (2) performing acellular treatment; (3) performing matrix metalloproteinase-7 treatment; and (4) performing vacuum freeze drying treatment. The low-immunogenicity pig dermal support is manufactured by using pig skin as a raw material, aiming at maintaining low-immunogenicity ingredients of pig dermal collagenous fiber and the like and natural three-dimensional structures based on the low-immunogenicity ingredients, removing (eliminating) high-immunogenicity ingredients such as cell and stromatin (such as laminin and fibronectin), and using means of skin material taking and treatment improvement, acellular method optimization, dematrix protein technique establishment, cross-linking agent optimization, vacuum freeze drying technique and the like. According to the method, the purposes of reducing the pig dermal immunogenicity to the level which ensures that the human body can be tolerated and synchronously maintaining the natural three-dimensional structure of the pig skin so as to guide 'ordered' regeneration and reconstruction of human derma in an orginzation mode of in-situ construction organization engineering are reached; and the problems or the prior art are solved.

The invention provides a rabies vaccine for human beings, which contains an outer membrane fragment of a split rabies virus particle and tetanus toxoid; the outer membrane fragment comprises furcella and matrix protein, wherein each dosage of rabies vaccine for human beings contains 10-150 micrograms of virus protein; and the dosage of the tetanus toxoid is 3-10 Lf / dosage. Compared with the existing virus purification stock solution, the rabies vaccine for human beings contains less other proteins, has higher immunogenicity and effect, and is more secure for use.

Described herein are vaccines and the use of naked DNA and / or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and / or the 1957 H2N2 and / or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and / or RNA encoding Neuraminidase (NA) and / or matrix protein (M) and / or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and / or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed.

The invention provides rabies vaccine for human being. The vaccine comprises an outer membrane segment of cracked rabies complete viral particles and tetanus toxoid, and the outer membrane segment comprises spike and matrix protein. Each dose of the rabies vaccine comprises 10 to 100 micrograms of viral protein; the dosage of the tetanus toxoid is 2 Lf / dose to 10 Lf / dose; and the dosage of aluminum phosphate adjuvant is 0.5mg / dose. Compared with the existing virus purified stock solution, the rabies vaccine for human being has the advantages that the content of impurity protein is greatly reduced, the immunogenicity and the potency are high, and the rabies vaccine is safer to use.

The invention discloses a recombinant homologous avian H1N1 influenza virus inactivated vaccine strain (JS40 / PR8) as well as a preparation method and an application of the inactivated vaccine strain. The recombinant avian H1N1 influenza virus inactivated vaccine strain takes A / swine / Jiangsu / 40 / 2011 (H1N1) as genetic donors of surface hemagglutinin (HA) and neuraminidase (NA), and influenza virus A / PR / 8 / 34(H1N1) as donors of six internal genes of a polymerase PB2 subunit, a polymerase PB1 subunit, a polymerase PA subunit, nucleoprotein (NP), a matrix protein (M) and non-structural protein (NS); the vaccine strain is obtained by natural recombination; and the preservation number of the vaccine strain is CCTCC NO:V201419. The invention also discloses a method for building the recombinant homologous avian H1N1 influenza virus inactivated vaccine strain, and an application of the homologous recombinant avian H1N1 influenza virus inactivated vaccine strain for preventing homologous avian H1N1 influenza of animals or people.

Short biologically active tetrapeptides are disclosed that are comprised of the sequences GxxG and PxxP where G (glycine) and P (proline) are maintained and x is a variable amino acid. The peptides can be used singly or in combination to stimulate production of extracellular matrix proteins in skin. A rapid, low-cost method of producing heterogenous formulations of tetrapeptides is disclosed.

The invention provides a composition and a preparing method and beauty preparation thereof. The composition comprises 30-70 volume parts of cell growth factor solutions, 30-70 volume parts of high-concentration blood platelet plasma, and adipose-derived stem cells with the concentration of 0.1*10<6>-2*10<6> / mL. Compared with the prior art, the composition is used for the beauty preparation, and the cell growth factor is a high-activity factor capable of promoting cell growth and promoting angiogenesis, wound healing and tissue damage repairing; the high-concentration blood platelet plasma is beneficial for binding cells and cell surface receptors and improving release of extracellular matrix protein and has a remarkable effect on removing wrinkles and relieving scars and stains; the adipose-derived stem cells can secrete various activity factors with remarkable biological functions, and the three substances interact to improve the wrinkle removal function of the beauty preparation.

The invention provides a kit for diagnosis of early non-small cell lung cancer. A marker of the kit is protein of serum exosomes, and the exosome protein is exosome human fetuin A, namely AHSG or / andexosome extracellular matrix protein-1, namely ECM-1. The content of the marker in a sample is detected, and if the content of the marker in the sample is greater than the critical value range thereof, a tester can preliminarily judge that the sample has larger risk of non-small cell lung cancer. The marker in the kit is simple to extract, the preparation is convenient and rapid, the detection process is simple, and the kit has a good diagnostic effect on early non-small cell lung cancer.

The present invention provides a swine fever virus chimeric type virus-like particle, a preparation method thereof, an application thereof and a vaccine, and belongs to the technical fields of bioengineering and virus vaccines. The swine fever virus chimeric type virus-like particle selects a Gag precursor protein of retroviruses as a matrix protein and swine fever virus envelope proteins E0 and E2 as surface membrane proteins to self-assemble into the ideal and functional virus-like particle, weaknesses of a subunit protein vaccine are overcome, and immunogenicity, safety and stability of thevaccine are effectively improved. The swine fever virus chimeric type virus-like particle can be prepared in large quantities by constructing expression vectors to transfect cells. The swine fever virus chimeric type virus-like particle can be applied to prepare the vaccine for preventing swine fever epidemic diseases, a swine fever virus antibody detection preparation or a swine fever virus epidemic disease monitoring preparation, and has a relatively good practical application value.

The present invention provides a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of extracellular matrix proteins of a human and a mouse. By specifically inhibiting the RGD sequence-mediated adhesion, exertion of efficient effects on diseases such as inflammation, cancer, infectious disease, autoimmune diseases and osteoporosis and reduction in adverse effects can be expected at the same time. Therefore, better treatment methods can be provided to these diseases.

The present invention provides a composition of matter, comprising: DNA encoding a viral Vpx protein fused to DNA encoding a protein. In another embodiment of the present invention, there is provided a composition of matter, comprising: DNA encoding a viral Vpr protein fused to DNA encoding a protein. The present invention further provides DNA, vectors and methods for expressing a lentiviral pol gene in trans, independent of the lentiviral gag-pol. A gene transduction element is optionally delivered to a lentiviral vector according to the present invention. Also provided are various methods of delivering a virus inhibitory molecule to a target in an animal. Further provided is a pharmaceutical composition.

The invention relates to the biology field, in particular to a monoclonal antibody of influenza virus matrix protein M1 and application of the monoclonal antibody. The monoclonal antibody of influenzavirus matrix protein comprises a heavy chain variable region and a light chain variable region, amino acid sequences of the CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ IDNO.1-3 separately; and amino acid sequences of the CDR1, CDR2 and CDR3 of the light chain variable region are shown in SEQ ID NO.4-6 separately. The monoclonal antibody can specifically recognize andbind multiple subtypes of influenza virus matrix protein M1, has broad spectrum applicability among influenza virus subtypes, has higher specificity and sensitivity, can be well applied to western blotting experiments, indirect immunofluorescence experiments, immunoprecipitation technologies and the like and has higher application values.